"Whatever options exist to make this a faster process, I think they are going to be leveraged." One likely scenario: The agency could green-light these peptides in the interim by placing them on what's known as the "Category One list." That would give compounding pharmacies cover to begin making these products sooner, while the longer rulemaking process plays out
Its whats known as a dual-action medication
J Membr Biol 138:113120 Bastien-Dionne PO, Valenti L, Kon N, Gu W, Buteau J (2011) Glucagon-like peptide-1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic -cell mass expansion
Researchers administered a one-time intraperitoneal injection (BPC 157 (200 or 2 g/kg) or 0.9% NaCl (5 ml/kg) 10 minutes after injury and concluded that all of the injured rats that received BPC-157 exhibited consistent clinical improvement [25]
House Bill 729, Jimmie's Law, was filed on Wednesday